Perception of alopecia by patients requiring chemotherapy for non-small-cell lung cancer: A willingness to pay study

Bernard, Mélisande; Brignone, M.; Adehossi, A.; Pefoura, S; Briquet, Caroline; Chouaïd, C.; Tilleul, P.

doi:10.1016/j.lungcan.2010.07.004

Cited by 16 publications

(12 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…() and Bernard et al . () and the treatment trade‐off study by Brundage et al . () had different focuses compared to the previously described studies.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Preferences of lung cancer patients for treatment and decision-making: a systematic literature review

et al. 2015

View full text Add to dashboard Cite

The consideration of patient preferences in decision-making has become more important, especially for life-threatening diseases such as lung cancer. This paper aims to identify the preferences of lung cancer patients with regard to their treatment and involvement in the decision-making process. We conducted a systematic literature review from 12 electronic databases and included studies published between 2000 and 2012. A total of 20 studies were included in this review. These revealed that lung cancer patients do have preferences that should be considered in treatment decisions; however, these preferences are not homogenous. We found that patients often consider life extension to be more important than the health-related quality of life or undesirable side effects. This preference seems to depend on patient age. Nausea and vomiting are the most important side effects to be avoided; the relevance of other side effects differs highly between subgroups. The majority of lung cancer patients, nevertheless, seem to prefer a passive rather than an active role in decision-making, although the self-reported preferences differed partly from the physicians' perceptions. Overall, we identified an urgent need for larger studies that are suitable for subgroup analyses and incorporate multi-attributive measurement techniques.

show abstract

“…() and Bernard et al . () and the treatment trade‐off study by Brundage et al . () had different focuses compared to the previously described studies.…”

Section: Resultsmentioning

confidence: 99%

“…() and Bernard et al . () showed the high relevance of gender‐specific preferences. These authors found that alopecia was more relevant to female patients.…”

Section: Discussionmentioning

confidence: 99%

Preferences of lung cancer patients for treatment and decision-making: a systematic literature review

et al. 2015

View full text Add to dashboard Cite

show abstract

“…10 Importantly bendamustine does not commonly cause alopecia which can be a consideration for many lung cancer patients concerned about appearance. 11,12 It also does not routinely cause either neuropathy or infusion reactions, and as such, does not require corticosteroids for premedication.…”

Section: Discussionmentioning

confidence: 99%

Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer

Lammers

Shyr

et al. 2014

Journal of Thoracic Oncology

View full text Add to dashboard Cite

Introduction To determine the time to progression (TTP), response rate, and toxicity for North American patients with relapsed small cell lung cancer (SCLC) treated with bendamustine in the second or third line setting. Methods Patients with relapsed, histologically confirmed SCLC were eligible for enrollment on study. The study population included patients with both chemotherapy sensitive and resistant disease treated with up to two prior lines of chemotherapy. Patients were treated with bendamustine 120 mg/m2 on days 1 and 2 of a 21-day cycle for up to 6 cycles. Primary endpoint was TTP; secondary endpoints included toxicity, response rate (RR), and overall survival (OS). Results Fifty-nine patients were accrued, 50 patients met eligibility for enrollment. The median age of patients was 62, and 56% were male. Twenty-nine patients (58%) had chemotherapy sensitive disease. Median TTP was 4.0 months (95% C.I. 3.3–5.4), median OS was 4.8 months (95% C.I. 3.8–6.3), and the RR was 26% (95% C.I. 13.3%–39.5%). Patients with chemosensitive disease had a median TTP of 4.2 months (95% C.I. 3.3–6.0) compared to 3.4 months (95% C.I. 2.7–∞) for chemotherapy resistant disease. The response rate was 33% (95% C.I. 14.2%–51.8%) in patients with chemosensitive disease and 17% (95% C.I. 0%–34.4%) in those with chemoresistant disease. The most common grade 3/4 adverse events were fatigue (20%), dyspnea (12%), and anemia (12%). Conclusions Bendamustine has modest activity in relapsed SCLC similar to other agents evaluated in this patient population.

show abstract

“…Nursing studies that handle alopecia that accompanies chemotherapy researched the change in body image caused by alopecia (Frith et al, 2007), male patient's experience of alopecia (Hamada et al, 2007), the influence on breast cancer patient's quality of life (QOL) due to alopecia resulting from chemotherapy and their awareness regarding alopecia (Hilton et al, 2008;Lemieux et al, 2008;Bernard et al, 2011;Can et al, 2012;Kim et al, 2012). Batchelor (2001) noted that a patient's loss of hair signifies the loss of hope to live and disappearance of the patient's individuality and attractiveness.…”

Section: Introductionmentioning

confidence: 99%

Psychosocial Reaction Patterns to Alopecia in Female Patients with Gynecological Cancer undergoing Chemotherapy

Ishida

Ishida²,

Kanda³

2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Perception of alopecia by patients requiring chemotherapy for non-small-cell lung cancer: A willingness to pay study

Cited by 16 publications

References 24 publications

Preferences of lung cancer patients for treatment and decision-making: a systematic literature review

Preferences of lung cancer patients for treatment and decision-making: a systematic literature review

Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer

Psychosocial Reaction Patterns to Alopecia in Female Patients with Gynecological Cancer undergoing Chemotherapy

Contact Info

Product

Resources

About